docetaxel anhydrous has been researched along with Sarcoma in 58 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (13.79) | 18.2507 |
| 2000's | 18 (31.03) | 29.6817 |
| 2010's | 27 (46.55) | 24.3611 |
| 2020's | 5 (8.62) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, HY; Hu, C; Huang, ZD; Lin, LL; Liu, ZZ; Wei, RX | 1 |
| Belitsky, GA; Bokhyan, BY; Burov, DA; Fetisov, TI; Fomina, LY; Kirilin, EM; Kirsanov, KI; Kozlov, NA; Laletina, LA; Lesovaya, EA; Makhmudova, LF; Manikaylo, AE; Mekheda, LV; Moiseeva, NI; Scherbakov, AM; Vilkova, AS; Yakubovskaya, MG; Zinovieva, VY | 1 |
| Abe, S; Akisue, T; Asanuma, K; Emori, M; Fukuda, H; Furuta, T; Hatano, H; Hiraga, H; Hiraoka, K; Hiruma, T; Iwamoto, Y; Katagiri, H; Kataoka, T; Kawai, A; Kawano, M; Kawashima, H; Machida, R; Matsumoto, Y; Morii, T; Nagano, A; Nakayama, R; Nishida, Y; Okuma, T; Outani, H; Ozaki, T; Suehara, Y; Takenaka, S; Takeyama, M; Tanaka, K; Toguchida, J; Tsukushi, S; Watanuki, M; Yamamoto, T; Yonemoto, T | 1 |
| Barwad, A; Bhatnagar, S; Bhoriwal, S; Dhamija, E; Kumar, A; Mridha, AR; Rastogi, S; Shamim, SA; Tansir, G | 1 |
| Chen, J; Jing, Z; Ma, P; Ning, E; Wang, X; Wang, Z; Wei, G | 1 |
| Ahn, JH; An, H; Choi, Y; Kim, YH; Kim, YJ; Lee, J; Lim, HY; Lim, SH; Park, KH; Park, YS; Suh, DC; Yun, MS | 1 |
| Chiba, N; Imai, H; Ishioka, C; Komine, K; Mori, T; Ohori, H; Okada, Y; Saijo, K; Shimodaira, H; Shirota, H; Takahashi, M; Takahashi, S | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Bouvet, M; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Razmjooei, S; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N; Zhang, Z | 1 |
| Constantinidou, A; Jones, RL; Loggers, E; Pollack, S; Rodler, E | 1 |
| Deslandes, A; Lazar, V; Massard, C; Mery-Mignard, D; Ozoux, ML; Soria, JC; Tolcher, AW | 1 |
| Egerer, G; Ho, AD; Kosely, F; Schmier, JW; Schmitt, T; Wuchter, P | 1 |
| Antoine, M; Bonnette, P; Cadranel, J; Cazes, A; Duruisseaux, M; Girard, N; Mazieres, J; Monnet, I; Ung, M; Vieira, T; Wislez, M | 1 |
| Gong, X; Jiang, S; Zhao, X; Zu, Y | 1 |
| Araki, N; Fukuda, H; Hiraga, H; Iwamoto, Y; Kataoka, K; Kawai, A; Kimura, A; Matsumine, A; Matsunobu, T; Mizusawa, J; Oda, Y; Tanaka, K | 1 |
| Andreou, D; Busemann, C; Ehninger, G; Gerdes, S; Pink, D; Reichardt, P; Richter, S; Schuler, MK; Tunn, PU | 1 |
| Guo, H; Liu, Y; Yang, S; Yao, S; Yao, Z; Zhao, Y | 1 |
| Kord Valeshabad, A; Mieler, WF; Setlur, V; Shahidi, M; Thomas, M | 1 |
| Baker, LH; Biermann, JS; Chugh, R; Davis, EJ; Feng, M; Jacobson, J; Lucas, DR; Metko, G; Reinke, D; Schuetze, SM; Wong, SL; Zalupski, MM; Zhao, L; Zyczynski, L | 1 |
| Blomen, V; Brummelkamp, TR; Hoogstraat, M; Janssen, L; Lips, EH; Neefjes, J; Pang, B; Qiao, X; van der Zanden, SY; Wessels, L; Wijdeven, RH | 1 |
| Agulnik, M; Carvajal, RD; Chi, P; Chmielowski, B; Crago, AM; D'Angelo, SP; Dickson, MA; Ezeoke, MO; Gounder, MM; Hameed, M; Healey, JH; Keohan, ML; Landa, J; Luke, JJ; Munhoz, RR; Qin, LX; Schwartz, GK; Singer, S; Singh, AS; Tap, WD; Van Tine, BA | 1 |
| Asaftei, S; Cesari, M; Coccoli, L; Fagioli, F; Ferrari, S; Grignani, G; Jones, RL; Longhi, A; Marchesi, E; Meazza, C; Paioli, A; Palmerini, E; Picci, P; Pollack, SM; Tamburini, A | 1 |
| Hua, H; Liang, Q; Miao, J; Sun, P; Xu, Y; Zhang, N; Zhao, Y | 1 |
| Chuman, H; Hatano, H; Hiraga, H; Hosaka, M; Iwamoto, Y; Joyama, S; Kaya, M; Kubo, T; Morioka, H; Nagano, A; Nishida, Y; Takahashi, M; Tanaka, K; Toguchida, J; Tsumura, H; Yoshikawa, H | 1 |
| Cruz, CO; de Torres, C; Mora, J; Parareda, A | 1 |
| Bui-Nguyen, B; Italiano, A; Toulmonde, M | 1 |
| Hensley, ML | 1 |
| Arias-Pulido, H; Bocklage, T; Cerilli, LA; Eberhardt, S; Lee, SJ; Movva, S; Muller, CY; Purdy, M; Quinn, R; Rabinowitz, I; Schmit, B; Snyder, D; Verschraegen, CF | 1 |
| Ahn, JH; Lee, EM; Lee, J; Park, KH; Rha, SY | 1 |
| Alazraki, A; Brill, P; Clark, D; George, BA; Katzenstein, HM; Martin, M; Olson, TA; Qayed, M; Rapkin, L; Wasilewski-Masker, K | 1 |
| Alici, S; Alkiş, N; Benekli, M; Berk, V; Büyükberber, S; Camci, C; Coskun, U; Esbah, O; Kaya, AO; Ozdemir, NY; Ozkan, M; Sevinc, A; Ulas, A | 1 |
| Burnside, N; MacGowan, SW | 1 |
| Eshun, F; Hingorani, P; Watanabe, M; White-Collins, A | 1 |
| Arai, Y; Endo, M; Hagisawa, S; Hiramatu, M; Hoshi, S; Ohyama, C; Satoh, M; Watanabe, R | 1 |
| von Mehren, M | 1 |
| Baker, LH; Biermann, JS; Couwlier, C; Lee, JS; Leu, KM; Ostruszka, LJ; Palazzolo, K; Shewach, D; Sondak, V; Zalupski, M | 1 |
| Chuman, H | 1 |
| Bay, JO; Blay, JY; Brain, E; Bui, NB; Cherix, S; Chevreau, C; Cioffi, A; Coindre, JM; Emile, G; Fayette, J; Isambert, N; Kwiatkowski, F; Le Cesne, A; Leyvraz, S; Penel, N; Peyrade, F; Piperno-Neumann, S; Ray-Coquard, I | 1 |
| Byrd, R; Chen, Z; Dunaway, R; Krailo, M; Monteleone, P; Reaman, G; Sato, J; Seibel, N; Strain, J; Zwerdling, T | 1 |
| Budd, GT; Elson, P; Suppiah, R; Wood, L | 1 |
| Admirand, JH; Bueso-Ramos, CE; Ford, RJ; Jiang, L; Moran, C | 1 |
| Baker, LH; Benjamin, RS; Fanucchi, M; Harmon, DC; Hensley, ML; Maki, RG; Okuno, SH; Patel, SR; Priebat, DA; Reinke, D; Samuels, B; Schuetze, SM; Thall, PF; Wathen, JK | 1 |
| Maki, RG | 1 |
| Bailly, C; Bay, JO; Cabrespine, A; Gilliot, O; Gimbergues, P; Mishellany, F; Vincent, C | 1 |
| Sleijfer, S; Verweij, J | 1 |
| Bauer, S; Ebeling, P; Eisele, L; Flasshove, M; Moritz, T; Schuett, P; Schuette, J; Seeber, S | 1 |
| Aamdal, S; Catimel, G; Sternberg, C; Sulkes, A; van Hoesel, Q; Verweij, J; Wolff, I | 1 |
| Catimel, G; Clavel, M; Kerbrat, P; Kerger, J; Tursz, T; van Glabbeke, M; van Hoesel, QG; van Oosterom, AT; van Pottelsberghe, C; Verweij, J | 1 |
| Verweij, J | 1 |
| Ebbert, LP; Edmonson, JH; Gerstner, JB; Jung, SH; McGaw, H; Nascimento, AG | 1 |
| Valero, V | 1 |
| Bodin, F; Dumontet, C; Michal, Y | 1 |
| Orel, NF | 1 |
| Brodowicz, T; Köstler, WJ; Wiltschke, C; Zielinski, CC | 1 |
| Baker, LH; Bruno, R; Hirth, J; Schott, A; Strawderman, M; Watkins, PB | 1 |
| Buesa, J; Coleman, R; di Paola, ED; Judson, IR; Lee, SM; Ruka, W; Seynaeve, C; Tonelli, D; van Glabbeke, M; van Hoessel, R; Verweij, J | 1 |
| Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC | 1 |
| Brandl, M; Burger, AM; Fiebig, HH; Massing, U; Moog, R; Schubert, R; Schüler, J; Unger, C | 1 |
10 review(s) available for docetaxel anhydrous and Sarcoma
| Article | Year |
|---|---|
The evolution of systemic therapy in sarcoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chordoma; Deoxycytidine; Dermatofibrosarcoma; Dioxoles; Docetaxel; Drug Resistance, Neoplasm; Gemcitabine; Hemangiosarcoma; Humans; Osteosarcoma; Proteasome Inhibitors; Receptor, IGF Type 1; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin | 2013 |
[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Docetaxel; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Leiomyosarcoma; Liposarcoma; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; Trabectedin | 2010 |
Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Sarcoma; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2010 |
Malignant primary cardiac tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cardiac Surgical Procedures; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Doxorubicin; Fatal Outcome; Female; Gemcitabine; Heart Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Myxoma; Neoplasm Recurrence, Local; Reoperation; Sarcoma; Taxoids; Time Factors; Treatment Outcome | 2012 |
Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Carboplatin; Carcinoma, Renal Cell; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Kidney Neoplasms; Neoplasm Staging; Nephrectomy; Paclitaxel; Sarcoma; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
New therapeutic strategies for soft tissue sarcomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Docetaxel; Epothilones; Guanidines; Humans; Indoles; Isoquinolines; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Pyrroles; Sarcoma; Sirolimus; Sunitinib; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin | 2003 |
[Current strategy of chemotherapy for reflactory bone and soft tissue sarcomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Imatinib Mesylate; Lung Neoplasms; Piperazines; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Taxoids | 2004 |
Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Synergism; Gemcitabine; Humans; Sarcoma; Taxoids | 2007 |
[Docetaxel and gemcitabine combination in soft-tissue sarcomas treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Sarcoma; Taxoids | 2007 |
[Taxotere in various solid tumors].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melanoma; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 1998 |
24 trial(s) available for docetaxel anhydrous and Sarcoma
| Article | Year |
|---|---|
Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Doxorubicin; Febrile Neutropenia; Gemcitabine; Humans; Ifosfamide; Sarcoma; Soft Tissue Neoplasms | 2022 |
A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Quality of Life; Sarcoma; Sarcoma, Synovial; Soft Tissue Neoplasms; Treatment Outcome | 2023 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Receptor, IGF Type 1; Sarcoma; Taxoids; Treatment Outcome; Vomiting; Young Adult | 2013 |
Gemcitabine and docetaxel for metastatic soft tissue sarcoma - a single center experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2013 |
A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Japan; Male; Middle Aged; Neoplasm Staging; Postoperative Period; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Hospitalization; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Michigan; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Radiotherapy, Adjuvant; Sarcoma; Soft Tissue Neoplasms; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2015 |
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Neoadjuvant Therapy; Pyrimidines; Sarcoma; Sulfonamides; Taxoids; Treatment Outcome | 2015 |
Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Osteosarcoma; Outpatients; Remission Induction; Salvage Therapy; Sarcoma; Sarcoma, Ewing; Sarcoma, Synovial; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Proportional Hazards Models; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Soft Tissue Neoplasms; Taxoids; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Sarcoma; Taxoids; Young Adult | 2012 |
Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Hematologic Diseases; Humans; Infant; Male; Neoplasm Grading; Recurrence; Retrospective Studies; Sarcoma; Survival Rate; Taxoids; Time Factors | 2012 |
Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Middle Aged; Nausea; Neutropenia; Retrospective Studies; Sarcoma; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome | 2006 |
Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Docetaxel; Female; Glioma; Humans; Infant; Male; Neoplasm Recurrence, Local; Sarcoma; Taxoids | 2006 |
Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Doxorubicin; Female; Humans; Ifosfamide; Male; Maximum Tolerated Dose; Middle Aged; Sarcoma; Survival Analysis; Taxoids | 2006 |
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Sarcoma; Taxoids; Treatment Outcome | 2007 |
Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Head and Neck Neoplasms; Humans; Melanoma; Middle Aged; Neoplasms; Paclitaxel; Sarcoma; Stomach Neoplasms; Taxoids | 1995 |
Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Europe; Female; Humans; Leukopenia; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Remission Induction; Sarcoma; Soft Tissue Neoplasms; Taxoids; Thrombocytopenia | 1994 |
Docetaxel: an interesting new drug for the treatment of head and neck cancers and soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Sarcoma; Taxoids | 1995 |
Phase II study of docetaxel in advanced soft tissue sarcomas.
Topics: Adult; Aged; Alopecia; Anorexia; Antiemetics; Antineoplastic Agents, Phytogenic; Cause of Death; Dexamethasone; Diarrhea; Diphenhydramine; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leiomyosarcoma; Leukopenia; Male; Middle Aged; Nausea; Paclitaxel; Patient Selection; Premedication; Remission Induction; Sarcoma; Taxoids; Uterine Neoplasms; Vomiting | 1996 |
Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclophosphamide; Dexamethasone; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Premedication; Remission Induction; Sarcoma; Taxoids | 1997 |
The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Erythromycin; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Mixed Function Oxygenases; Orosomucoid; Paclitaxel; Sarcoma; Soft Tissue Neoplasms; Taxoids | 2000 |
Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and b
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cross-Over Studies; Disease Progression; Docetaxel; Doxorubicin; Female; Humans; Male; Paclitaxel; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2000 |
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Sarcoma; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2001 |
24 other study(ies) available for docetaxel anhydrous and Sarcoma
| Article | Year |
|---|---|
m6A Modification Patterns With Distinct Immunity, Metabolism, and Stemness Characteristics in Soft Tissue Sarcoma.
Topics: Adenosine; Antineoplastic Agents; Deoxycytidine; DNA Copy Number Variations; DNA Methylation; Docetaxel; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy; Kaplan-Meier Estimate; Sarcoma | 2021 |
Analysis of Multiple Drug Resistance Mechanism in Different Types of Soft Tissue Sarcomas: Assessment of the Expression of ABC-Transporters, MVP, YB-1, and Analysis of Their Correlation with Chemosensitivity of Cancer Cells.
Topics: ATP-Binding Cassette Transporters; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasm Recurrence, Local; Sarcoma; Soft Tissue Neoplasms | 2022 |
Docetaxel loaded mPEG-PLA nanoparticles for sarcoma therapy: preparation, characterization, pharmacokinetics, and anti-tumor efficacy.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Cell Line, Tumor; Chemistry, Pharmaceutical; Docetaxel; Dose-Response Relationship, Drug; Drug Carriers; Drug Liberation; Mice, Inbred ICR; Nanoparticles; Particle Size; Polyesters; Polyethylene Glycols; Random Allocation; Rats; Sarcoma | 2021 |
Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Sarcoma; Taxoids; Young Adult | 2018 |
Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2017 |
The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Mice, Nude; Middle Aged; Sarcoma; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Giant Cell Tumors; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Sarcoma; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Preparation, characterization, and antitumor activities of folate-decorated docetaxel-loaded human serum albumin nanoparticles.
Topics: Animals; Animals, Outbred Strains; Antineoplastic Agents; Biological Transport; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Carriers; Drug Compounding; Drug Delivery Systems; Folic Acid; Humans; Liver Neoplasms, Experimental; Mice; Nanoparticles; Particle Size; Random Allocation; Sarcoma; Serum Albumin; Serum Albumin, Human; Solubility; Surface Properties; Taxoids | 2015 |
Gemcitabine and docetaxel for epithelioid sarcoma: results from a retrospective, multi-institutional analysis.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Sarcoma; Survival Rate; Taxoids; Treatment Outcome | 2014 |
[Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Leiomyosarcoma; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Sarcoma; Taxoids; Treatment Outcome | 2014 |
Posterior segment toxicity after gemcitabine and docetaxel chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Staging; Neoplasms, Unknown Primary; Photoreceptor Cells, Vertebrate; Sarcoma; Taxoids; Tomography, Optical Coherence; Uveal Diseases; Vision Disorders; Visual Acuity | 2015 |
Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Capecitabine; Carcinoma; Chromosomal Proteins, Non-Histone; CRISPR-Cas Systems; Cyclophosphamide; DNA Helicases; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Profiling; Genome-Wide Association Study; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Neoplasm Proteins; Nuclear Proteins; RNA Interference; RNA, Small Interfering; Sarcoma; SMARCB1 Protein; Taxoids; Topoisomerase II Inhibitors; Topotecan; Transcription Factors; Triple Negative Breast Neoplasms | 2015 |
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone.
Topics: Adolescent; Adult; Aged; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Osteosarcoma; Recurrence; Sarcoma; Taxoids; Treatment Outcome | 2016 |
Pharmacokinetics, tissue distribution and anti-tumor effect of low density lipoprotein peptide conjugated submicron emulsions.
Topics: Administration, Intravenous; Amino Acid Sequence; Animals; Antineoplastic Agents; Docetaxel; Emulsions; Male; Mice; Particle Size; Peptides; Rats, Sprague-Dawley; Receptors, LDL; Sarcoma; Static Electricity; Taxoids; Tissue Distribution | 2016 |
Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Feasibility Studies; Gemcitabine; Humans; Japan; Middle Aged; Neutropenia; Osteosarcoma; Pneumonia; Retrospective Studies; Sarcoma; Taxoids; Treatment Outcome; Tubulin Modulators; Young Adult | 2016 |
Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Prognosis; Retrospective Studies; Salvage Therapy; Sarcoma; Survival Rate; Taxoids; Young Adult | 2012 |
Gemcitabine, docetaxel, and bevacizumab in relapsed and refractory pediatric sarcomas.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Sarcoma; Taxoids; Vascular Endothelial Growth Factor A | 2012 |
Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Interactions; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Taxoids | 2004 |
Mediastinal follicular dendritic cell sarcoma involving bone marrow: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Dendritic Cells, Follicular; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Immunoenzyme Techniques; Mediastinal Neoplasms; Methotrexate; Middle Aged; Sarcoma; Taxoids; Treatment Outcome | 2006 |
Trial methodology in soft tissue sarcomas; the 'one plus one is three or zero' phenomenon.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bias; Deoxycytidine; Disease Progression; Docetaxel; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Research Design; Sarcoma; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Middle Aged; Neoplasm Staging; Palliative Care; Retrospective Studies; Sarcoma; Survival Analysis; Taxoids; Uterine Neoplasms | 2008 |
Potential interactions between antitubulin agents and temperature: implications for modulation of multidrug resistance.
Topics: Antineoplastic Agents, Phytogenic; Biological Transport; Cell Division; Cell Survival; Docetaxel; Drug Resistance, Multiple; Humans; Hyperthermia, Induced; Leukemia, Erythroblastic, Acute; Paclitaxel; Sarcoma; Taxoids; Temperature; Tumor Cells, Cultured; Vinblastine | 1998 |
Efficacy of docetaxel in the second-line treatment of locally advanced or metastatic soft tissue sarcoma after failure of chemotherapy with anthracycline or ifosfamide.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Male; Paclitaxel; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Taxoids | 1999 |
Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Deoxycytidine; Docetaxel; Gels; Gemcitabine; Half-Life; Humans; Liposomes; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Phospholipids; Sarcoma; Taxoids; Tissue Distribution; Transplantation, Heterologous; Urinary Bladder Neoplasms; Vindesine | 2002 |